CA-AIRGAIN
30.5.2024 14:56:33 CEST | Business Wire | Press release
Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, has signed a strategic Memorandum of Understanding (MOU) with Compal Electronics, Inc. (TAIEX: 2324), a global fortune 500 leader in smart device manufacturing, on a comprehensive plan for commercialization of a 5G Smart Fixed Wireless Access (FWA) technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530558164/en/
Yiyun Chang, Vice President at Compal Electronics, Inc. (left), shaking hands with Dr. Ali Sadri, CTO of Airgain, Inc., after signing a strategic MOU. (Photo: Business Wire)
The agreement signals a major step towards enabling mass production of this transformative technology which has the potential to substantially enhance 5G customer experience and mobile network operator (MNO) capabilities.
Airgain Smart LanternTM uses patent-pending smart beamforming technology to simplify end-user FWA deployment as well as reducing truck roll and professional installation, by automatically determining the direction of the best received and transmitted signal from the 5G cellular base station (gNb).
Preliminary testing results indicate a performance enhancement exceeding 25% in both throughput and range when compared to conventional indoor and outdoor omnidirectional Fixed Wireless Access (FWA) Customer Premises Equipment (CPE).
The MOU commits the two companies to a collaboration which will see them evaluate the technology’s 5G KPI enhancements and assess the feasibility, effectiveness, and opportunities for original equipment manufacturer (OEM) and original device manufacturer (ODM) for FWA device development.
At the heart of the innovation is Airgain’s first-of-its-kind smart antenna technology for 5G mid-band and C-band frequencies, and novel beamforming algorithms. When combined with COMPAL’s expertise in developing FWA modules leveraging leading 5G chipset providers, this will deliver a powerful value proposition to their customers.
According to the forecast presented in the Ericsson Mobility Report, the Fixed Wireless Access (FWA) market is projected to reach a valuation of $67 billion by the year 2028, which equates to a Compound Annual Growth Rate (CAGR) of 16% year-over-year. Smart Lantern's FWA technology holds the potential to significantly drive the adoption of FWA technology among Mobile Network Operators (MNOs).
Dr. Ali Sadri, CTO of Airgain, Inc., heralded the MOU as a significant moment in bringing Smart LanternTM to market, adding:
“As we embark on this ground-breaking journey towards enabling commercialization, the signing of this MOU with COMPAL signifies a strategic leap forward in realizing the full potential of our innovative product, Smart LanternTM.
“Having demonstrated its feasibility and generated tremendous excitement at Mobile World Congress, this MOU underscores our commitment to translating that enthusiasm into tangible market success. This momentous partnership solidifies Airgain's position as a trailblazer in delivering cutting-edge solutions that shape the future landscape of wireless communication.”
Yiyun Chang, Vice President at Compal Electronics, Inc., said:
“COMPAL’s mission is to foster collaborative innovation and make ideas happen. Our collaboration with Airgain is built on shared dedication to pushing the boundaries of what's possible in the telecommunications industry. We are confident that this partnership will not only meet but exceed the expectations of telecom equipment manufacturers (TEMs), MNOs, and system integrators (SI).
“Together, we are poised to redefine the standards and capabilities of wireless communication, reinforcing COMPAL’s commitment to delivering state-of-the-art solutions that shape the future of connectivity.”
For more information about Smart LanternTM visit airgain.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530558164/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom